Proteomic Screening for Serum Biomarkers for Cervical Cancer and Their Clinical Significance
Proteomic Screening for Serum Biomarkers for Cervical Cancer and Their Clinical Significance
复制标题
宫颈癌血清生物标志物的蛋白质组学筛查及其临床意义
DOI：
10.12659/msm.911478
复制
发表时间：
2019-01-09
影响因子：
3.1
通讯作者：
Zhang, Jing
中科院分区：
文献类型：
--
作者：
Chen, Yani;Xiong, Xiaofan;Zhang, Jing
Background: The present study aimed to determine serum markers for cervical cancer (CC) and to provide valuable references for clinical diagnosis and treatment.Material/Methods: Serum samples were collected from age-matched healthy control women, and from female CC patients before and after surgery. Serum biomarkers were selected by comparing serum peptides profiles among the 3 groups by magnetic bead-based weak cation - exchange chromatography fractionation combined with matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Probable serum biomarkers for cervical cancer were then further identified by liquid chromatography-electrospray ionization-tandem mass spectrometry system and the identified proteins were verified by enzyme-linked immunosorbent assay (ELISA).Results: Three peptide biomarkers were identified for distinguishing CC patients from normal individuals, and distinguishing preoperative CC patients from postoperative CC patients. Of these 3 identified protein peptide regions, 2 peptide regions - TKT (Peak 2, 2435.63 m/z, 499-524) and FGA (Peak 4, 2761.79 m/z, 603-629) - were identified as upregulated markers, and peptide region of APOA1 (Peak 9, 2575.3 m/z, 245-260) was identified as a downregulated biomarker in preoperative CC patients compared with healthy women.Conclusions: The present study provides a new method for identifying potential serum biomarkers for CC patients.
